We read with interest the recent article by Kim et al
1
regarding the effects of ABO incompatibility on outcome of allogeneic peripheral blood stem cell transplant (PBSCT). In their series, no cases of massive immune hemolysis were seen. However, because PBSCT grafts contain a statistically significantly higher number of B lymphocytes 2 and more activated B lymphocytes 2 as compared to bone marrow stem cell grafts, the incidence of immune-mediated hemolysis due to passenger, donor B lymphocytes may be as high as 22% in patients receiving an ABO-incompatible graft, 3, 4 depending on the post transplant immunosuppressive regimen employed. 4 ,5 In Kim's 1 series, about two-thirds of the patients received methotrexate as part of their immunosuppression regimen, which suppresses both antibody production by, and proliferation of, B lymphocytes. Inclusion of methotrexate prophylaxis has been suggested to prevent immune hemolysis in the setting of ABO incompatibility. 5 We report a case of immune-mediated hemolysis secondary to donor passenger B lymphocytes following myeloablative chemotherapy and HLA-matched, ABOmismatched PBSCT from an unrelated donor. The case demonstrates that methotrexate prophylaxis does not completely protect against massive immune hemolysis and also illustrates a definitive management strategy, namely emergent red blood cell exchange transfusion.
An otherwise healthy 38-year-old male with chronic myelogenous leukemia (CML) was referred to our institution after failing to achieve cytogenetic remission of his disease with imatinib mesylate (Gleevec s ) therapy despite appropriate dose titration. A donor matched at 10/10 alleles by high-resolution DNA typing was identified, and the patient received myeloablative therapy (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg) followed by infusion of filgrastim-mobilized donor PBSC.
The patient's blood group type was A positive and naturally occurring anti-B was detected at 1:4 in his serum. The donor was B positive. Anti-A antibodies were detected in the donor prior to mobilization of PBSC. The PBSCT was performed on day 0 without complication. Throughout the transfusion dependency period, group O red blood cells and group A platelets were utilized.
The patient developed grade I acute GvHD of the skin and grade III mucositis (by NCI CTCAE version 3.0). His immunosuppressive regimen included cyclosporin A (1.5 mg/kg intravenously begun on day À1) and methotrexate (10 mg/m 2 scheduled for days þ 1, þ 3, þ 6, and þ 11). Notably, the patient's day þ 11 dose of methotrexate was withheld secondary to mucositis.
On day þ 16, the patient developed fever and complained of dyspnea at rest. As shown in Table 1 , comparison of the patient's routine morning laboratory values with those at the time of symptoms suggested acute hemolysis. Review of the peripheral blood smear revealed Table 2 ) characterized this case as passenger lymphocyte syndrome. On day þ 7, the patient's blood still demonstrated a significant number of A cells, although his polyspecific direct antibody test (DAT) had become positive. Further testing showed anti-IgG to be negative; however, antiC3b,d was documented on his red blood cells. The indirect antiglobulin test was negative. From day þ 9 to day þ 14, the patient received 10 units of red blood cells empirically to maintain his hemoglobin above 8 g/dl. On day þ 11, the patient's red cells continued to be type group A; however, both anti-A and anti-B antibodies were identified in his serum. By day þ 14, the anti-A antibody had become strongly positive.
On day þ 16, arrangements were made for the patient to undergo urgent red blood cell exchange transfusion with 11 units of red blood cells. The patient tolerated the apheresis procedure well. Further clinically significant hemolysis did not occur. As seen in Table 2 , post exchange transfusion the proportion of A cells decreased, suggesting that removal of recipient red blood cells correlated with clinical improvement observed. He was subsequently discharged in good condition and continues to do well beyond day þ 100.
In summary, despite methotrexate prophylaxis, our patient experienced sudden, severe immune hemolysis due to passenger lymphocyte syndrome. Methotrexate may have initially suppressed or delayed significant clinical hemolysis but did not prevent it completely. While not reported in Kim's series, 1 our case illustrates the need for ongoing vigilance with regard to this severe complication of ABO incompatibility, even in the setting of methotrexate GvHD prophylaxis. Urgent, definitive therapy with red blood cell exchange transfusion led to a successful outcome in this instance. 
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